Wiring healthcare
By David Woods (david.woods@rxcomms.com) A pair of economists, Charles Jones of the University of California at Berkeley and Robert Hall of Stanford University, predict that the share of income devoted…
DetailsA new way for pharmaceutical companies and prescribers to interact?
By David Woods (david.woods@rxcomms.com) Call them Sermoans, Sermophiles, or just plain members, the 32,000 physicians enrolled in Sermo could be changing the way that pharmaceutical companies interact with healthcare professionals.…
DetailsYou need to know the global issues in health economics
By Robert Hand (robert.hand@rxcomms.com) As a health economist and outcomes researcher, you may work primarily within a single country. Naturally, you know the economic, regulatory, and management issues of that…
DetailsWhat is the value of outcomes research?
By Kevin Frick (kevin.frick@rxcomms.com) It is ironic that we should have to answer the question: “what is the value of outcomes research?” when outcomes research is a key component of…
DetailsAMWA Annual Conference 2007
By Robert Hand (robert.hand@rxcomms.com) Under the title Legacy of Leadership, the American Medical Writers Association (AMWA) held its 67th Annual Conference on October 11–13 in Atlanta, Georgia. About 1000 medical…
DetailsHOC people – Dennis M. Gross, PhD
By David Woods (david.woods@rxcomms.com) On January 1st 2006, Dr Dennis Gross retired from Merck after 28 years; the following day, he took up his present position as Associate Dean, Masters…
DetailsLetter to the editor
Our HOC People person this month, Dennis M. Gross, PhD, is an associate dean at Thomas Jefferson University where he also teaches courses in pharmacology and toxicology. He emailed us these thoughts on non-adherence.
DetailsMaking adherence work for your dollar (or pound, or euro…)
By Mary Gabb (mary.gabb@rxcomms.com) As we reported in last month’s HOC, the past few years have witnessed a surge of interest in the role of adherence in health economics research,…
DetailsOutsourcing clinical trials
By David Woods (david.woods@rxcomms.com) Writing in Pharmatech a couple of years ago, Dr Faiz Kermani observed that “many clinical trials are plagued by delays and setbacks that can cost pharmaceutical…
DetailsRx attracts strong interest at Dublin ISPOR Conference
By Ruth Whittington (ruth.whittington@rxcomms.com) The theme of this year’s ISPOR annual European Congress – the largest ever – was ‘Expanding Horizons’, and the Rx team took this very seriously, meeting…
Details